BR0311248A - Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino - Google Patents

Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino

Info

Publication number
BR0311248A
BR0311248A BR0311248-9A BR0311248A BR0311248A BR 0311248 A BR0311248 A BR 0311248A BR 0311248 A BR0311248 A BR 0311248A BR 0311248 A BR0311248 A BR 0311248A
Authority
BR
Brazil
Prior art keywords
long
ester
acting
contraception
hrt
Prior art date
Application number
BR0311248-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Henrik De Nijs
Hendrikus Adrianus Anton Voort
Dirk Leysen
Arij Jan Grootenhuis
Jaap Van Der Louw
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0311248A publication Critical patent/BR0311248A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR0311248-9A 2002-05-30 2003-05-22 Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino BR0311248A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30
PCT/EP2003/050188 WO2003101374A2 (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters

Publications (1)

Publication Number Publication Date
BR0311248A true BR0311248A (pt) 2005-03-15

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311248-9A BR0311248A (pt) 2002-05-30 2003-05-22 Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino

Country Status (26)

Country Link
US (1) US20050222114A1 (enExample)
EP (1) EP1513588B1 (enExample)
JP (1) JP2005532336A (enExample)
KR (1) KR20050005507A (enExample)
CN (1) CN1655848A (enExample)
AR (1) AR040129A1 (enExample)
AT (1) ATE394140T1 (enExample)
AU (1) AU2003246740B2 (enExample)
BR (1) BR0311248A (enExample)
CA (1) CA2487293A1 (enExample)
DE (1) DE60320786D1 (enExample)
ES (1) ES2305498T3 (enExample)
HR (1) HRP20041127A2 (enExample)
IL (1) IL165125A0 (enExample)
IS (1) IS7537A (enExample)
MX (1) MXPA04011798A (enExample)
NO (1) NO20044903L (enExample)
NZ (1) NZ536618A (enExample)
PE (1) PE20040042A1 (enExample)
PL (1) PL373295A1 (enExample)
RS (1) RS101004A (enExample)
RU (1) RU2322986C2 (enExample)
TW (1) TW200400041A (enExample)
UA (1) UA80703C2 (enExample)
WO (1) WO2003101374A2 (enExample)
ZA (1) ZA200409498B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
BR112020007673A2 (pt) * 2017-10-19 2020-10-13 Evestra, Inc. contraceptivos pró-fármaco de progestina de ação prolongada
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
EP4164743A2 (en) * 2020-06-11 2023-04-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
CN1135716A (zh) * 1993-12-27 1996-11-13 阿克佐诺贝尔公司 经皮吸收的药用制剂
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
TR200003743T2 (tr) * 1998-06-19 2001-07-23 Akzo Nobel N.V. Testosteron türevi.
WO1999067270A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Also Published As

Publication number Publication date
NZ536618A (en) 2007-06-29
RU2322986C2 (ru) 2008-04-27
EP1513588A2 (en) 2005-03-16
AR040129A1 (es) 2005-03-16
RU2004138809A (ru) 2005-06-10
US20050222114A1 (en) 2005-10-06
IL165125A0 (en) 2005-12-18
PE20040042A1 (es) 2004-01-31
DE60320786D1 (de) 2008-06-19
UA80703C2 (en) 2007-10-25
HK1072568A1 (en) 2005-09-02
TW200400041A (en) 2004-01-01
WO2003101374A2 (en) 2003-12-11
CN1655848A (zh) 2005-08-17
CA2487293A1 (en) 2003-12-11
PL373295A1 (en) 2005-08-22
WO2003101374A3 (en) 2004-02-26
AU2003246740B2 (en) 2009-01-08
MXPA04011798A (es) 2005-03-31
AU2003246740A1 (en) 2003-12-19
IS7537A (is) 2004-11-18
RS101004A (sr) 2006-10-27
ES2305498T3 (es) 2008-11-01
NO20044903L (no) 2005-02-25
HRP20041127A2 (en) 2005-02-28
EP1513588B1 (en) 2008-05-07
JP2005532336A (ja) 2005-10-27
KR20050005507A (ko) 2005-01-13
ZA200409498B (en) 2006-05-31
ATE394140T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
TR200200706T2 (tr) Nöropatik ağrı tedavisi için retigabin kullanımı.
UA81638C2 (ru) Композиция метронидазола для местного применения для лечения заболеваний аноректального и перианального участков
AU2002236604A1 (en) Condom with male genital desensitizer lubricant
EP1377245A4 (en) IMMUNOSTIMULATING COATING FOR SURGICAL DEVICES
BR0314016A (pt) Dispositivo para incontinência urinária intravaginal e método de alìvio de incontinência urinária feminina
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
BR9902191A (pt) Artigo absorvente
IL153648A0 (en) Novel testosterone ester formulation for human use
WO2005007112A3 (en) Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
CO5631449A2 (es) Nuevos esteres de etonogestrel
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
ZA200104923B (en) The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease.
BR0210101A (pt) Combinações antineoplásticas
ES2098967T3 (es) Cateter urinario externo.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2006042021A3 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
IS6130A (is) Bólgueyðandi meðhöndlun fyrir bólgu tengt smit
PL366009A1 (en) Methods and compositions for the treatment of inflammatory diseases
MXPA03001081A (es) Medicamento anti-inflamatorio.
BR0318195A (pt) bainha contraceptiva com construção de rebordo inteiriço
BR9915664A (pt) Estrutura de anel dessensibilizador
WO2003101374A3 (en) Use of new etonogestrel esters
BR0313589A (pt) Uso de extrato de germe de trigo fermentado como agente antiinflamatório
BR9814136A (pt) Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: N.V. ORGANON (NL)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.